GABA-Mimetic Agent Fengabine in the Treatment of Depression: An Overview

  • B. Musch
  • M. Garreau


The development of antidepressant drugs has traditionally been based on the potentiation of central monoaminergic synaptic activity. In order to dissociate the classic undesirable effects of antidepressants related to monoamine potentiation from the antidepressant effect, attempts have been made to discover new antidepressant drugs with other mechanisms of action. One of these new approaches suggests the involvement of γ-aminobutyric acid (GABA) in the pathogenesis of depression.1


Antidepressant Drug Clinical Global Impression Montgomery Asberg Depression Rate Scale Dysthymic Disorder Gaba Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lloyd KG, Morselli PL, Depoortere H, et al. The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav 1983; 18: 957.PubMedCrossRefGoogle Scholar
  2. 2.
    Musch B, Garreau M. An overview of the antidepressant activity of fengabine in open clinical studies. In Proceedings of the IVth World Congress of Biological Psychiatry, Philadelphia, 1985.Google Scholar
  3. 3.
    Musch B. Antidepressant activity of fengabine: a critical overview of the present results in open clinical studies. In Bartholini G, Lloyd KG, Morselli PL (eds): GABA and Mood Disorders: Experimental and Clinical Research (L.E.R.S. Monograph Series, Vol. 4 ). New York: Raven Press, 1986; 171 – 177.Google Scholar
  4. 4.
    Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382 – 385.PubMedCrossRefGoogle Scholar
  5. 5.
    Hamilton M. Development of a rating scale for primary depressive illness. Br J Psychiatry 1967; 6: 278 – 296.Google Scholar
  6. 6.
    Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976.Google Scholar
  7. 7.
    Brion S, Gailledreau J, Garreau M., et al. Double blind study of fengabine versus imipramine in depression. In preparation.Google Scholar
  8. 8.
    Bourgeois M, Escande M, Lepine JP, et al. Multicenter double blind study of fengabine versus clomipramine in major affective disorders. In preparation.Google Scholar
  9. 9.
    Samuelian JC, Ballereau J, Bordarier V, et al. Fengabine, a new GABA-mimetic agent, and clomipramine in the treatment of major depression—a double blind study. Submitted for publication.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • B. Musch
  • M. Garreau

There are no affiliations available

Personalised recommendations